Amgen Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD 12.19 B

Amgen Inc. Operating Cash Flow is USD 12.19 B for the Trailing 12 Months (TTM) ending March 31, 2025, a 50.59% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Amgen Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 8.10 B, a -6.09% change year over year.
  • Amgen Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 8.62 B, a -7.51% change year over year.
  • Amgen Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 9.32 B, a -10.95% change year over year.
  • Amgen Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 10.47 B, a 10.89% change year over year.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities